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Objectives: The study was designed to assess whether diazoxide-mediated cardioprotection might be used in
human subjects during cardiac surgery.
Methods: Forty patients undergoing coronary artery bypass grafting were randomized to receive intermittent
warm blood antegrade cardioplegia supplemented with either diazoxide (100 mmol/L) or placebo (n ¼ 20 in
each group). Mitochondria were assessed before and after ischemia and reperfusion in myocardial biopsy spec-
imens. Myocardial oxygen and glucose and lactic acid extraction ratios were measured before ischemia and in the
first 20 minutes of reperfusion. Hemodynamic data were collected, and troponin I, creatine kinase–MB, and
N-terminal prohormone brain natriuretic peptide levels were measured. All outcomes were analyzed by using
mixed-effects modeling for repeated measures.
Results: No deaths, strokes, or infarcts were observed. Patients received, on average, 36.2  1.2 mg of diazoxide
and 37.3  1.9 mg of placebo (P¼ .6). Diazoxide added to cardioplegia prevented mitochondrial swelling (8899
 474 vs 9273  688 pixels before and after the procedure, respectively; P ¼ .6) compared with that seen in the
placebo group (8474  163 vs 11,357  759 pixels, P ¼ .004). No oxygen debt was observed in the diazoxide
group. Glucose consumption and lactic acid production returned to preischemic values faster in the diazoxide
group. The following hemodynamic parameters differed between the diazoxide and placebo groups, respectively,
in the postoperative period: cardiac index, 3.0  0.09 versus 2.6  0.09 L $ min1 $ m2 (P ¼ .002); left cardiac
work index, 2.81  0.07 versus 2.31  0.07 kg/m2 (P<.001); oxygen delivery index, 420  14 versus 377  13
mL $ min1 $ m2 (P¼ .03); and oxygen extraction ratio, 29.3% 1.1% versus 32.6% 1.1% (P¼ .02). Post-
operative myocardial enzyme levels did not differ, but N-terminal prohormone brain natriuretic peptide levels
were lower in the diazoxide group (120  27 vs 192  29 pg/mL, P ¼ .04).
Conclusions: Supplementing blood cardioplegia with diazoxide is safe and improves myocardial protection dur-
ing cardiac surgery, possibly through its influence on the mitochondria.C
P
SSupplemental material is available online.
There is substantial evidence from in vitro and experimental
animal studies that diazoxide provides a strong myocardio-
protective effect.1 Diazoxide is a selective mitochondrial
adenosine triphosphate–sensitive potassium (KATP) channel
opener and is believed to induce a preconditioning state.1
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ically undetectable) mitochondrial volume increase, which
results in tighter apposition of specialized sites on internal
and external mitochondrial membranes associated with cou-
pling to cytosol creatine kinase.2 This allows for fatty acid
transport into the mitochondrion3 and speeds up oxidative
phosphorylation.4 Simultaneously, diazoxide prevents the
‘‘priming phase’’ of mitochondrial permeability transition
pore opening and thus pathologic mitochondrial swelling,
leading to eventual cell death.5 Recently, it has also been
postulated that diazoxide might exert its myocardioprotec-
tive action during ischemia through intracellular targets
other than mitochondrial KATP channels.
6,7 We have shown
in human atrial trabeculae that administering diazoxide at
the relatively high concentration of 100 mmol/L throughout
ischemia provides a significantly stronger cardioprotective
effect.8,9
Diazoxide has never been implemented in human studies,
apart from the trial in which it was administered systemically
as a preconditioning signal before cardiopulmonary bypass
(CPB).10 The present human study was designed to assessCardiovascular Surgery c Volume 137, Number 4 997
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SAbbreviations and Acronyms
AXC ¼ aortic crossclamping
CK-MB ¼ creatine kinase–MB
CPB ¼ cardiopulmonary bypass
KATP ¼ adenosine triphosphate–sensitive
potassium
NT-proBNP ¼ N-terminal prohormone brain
natriuretic peptide
O2ER ¼ oxygen extraction ratio
whether supplementing blood cardioplegia with 100 mmol/L
diazoxide is safe and confers a beneficial effect on myocar-
dial mitochondria,5,11,12 metabolism,11,13,14 function,8,9,15,16
and viability8,9,16,17 after ischemia and reperfusion, as sug-
gested by prior experimental in vitro and animal studies.
MATERIALS AND METHODS
The Medical University of Silesia Bioethics Committee approved the
study, and informed consent was obtained from all participating patients.
The study was performed on patients undergoing elective coronary artery
bypass grafting for triple-vessel coronary artery disease and stable angina.
Exclusion criteria included acute coronary syndrome, left ventricular ejec-
tion fraction of less than 35%, coexisting valvular disease of at least mod-
erate severity, coexisting illnesses that might influence perioperative risk,
and diabetes mellitus. We evaluated 162 patients over the time period of
13 months and identified 63 eligible patients, of whom 41 agreed to random-
ization. One patient was excluded because during the procedure, technical
difficulties forced us to reperform the anastomosis. The patient was found
to be in the placebo group once the study was unblinded. Intermittent
warm blood (37C) antegrade cardioplegia was used for myocardial protec-
tion. The patients were randomized based on a random-digit table to receive
100 mmol/L diazoxide or placebo as a cardioplegia supplement. Oxygenated
blood was infused through an aortic root needle at a rate of 300 mL/min. By
using a syringe pump, potassium chloride was added to keep the potassium
concentration at 20 mEq/l at induction and 10 mEq/L during maintenance.
Simultaneously, another syringe pump was used to supplement cardioplegia
with diazoxide (Eudemine Injection; Goldshield Pharmaceuticals Ltd,
Croydon, United Kingdom) to achieve a concentration of 100 mmol/L or
to infuse placebo (0.9% sodium chloride). Neither the perfusionist, the
anesthetist, nor the surgeon knew the content of the syringe. Each patient
was administered a 3-minute cardioplegia infusion (containing 21 mg of di-
azoxide/placebo) at induction and a 1.5-minute infusion as a maintenance
dose (containing 10 mg of diazoxide/placebo) every 12 to 15 minutes. An-
esthesia consisted of 15 mg of midazolam administered orally 1 hour before
surgical intervention; 0.2 mg/kg etomidate, 5 mg/kg fentanyl, and 0.1 mg/kg
pancuronium administered intravenously for anesthesia induction; and 0.1
mg $ kg1 $ h1 midazolam and 6 mg $ kg1 $ h1 fentanyl infusion for an-
esthesia maintenance. No anesthetic gases were used.
Hemodynamic Status
A pulmonary artery catheter was used to assess the hemodynamic profile
and the patient’s oxygen metabolism status preoperatively and within the
first postoperative 24 hours (see Appendix E1). During CPB, mean arterial
pressure, central venous pressure, and systemic vascular resistance index
were acquired before aortic crossclamping (AXC), immediately after every
dose of cardioplegia, 2 minutes later, and immediately before every next
dose of cardioplegia. Measurements were also obtained before removing
the AXC and before weaning the patient off CPB. Mean arterial pressure998 The Journal of Thoracic and Cardiovascular Suwas kept between 50 and 80 mm Hg by using glyceryl trinitrate infusion
and norepinephrine 1:100,000 1-mL boluses. All patients were weaned
off CPB by using 5 mg $ kg1 $ min1 dopamine infusion and 0.25 mg $
kg1 $ min1 glyceryl trinitrate, which are routinely used in our institution
to improve visceral perfusion and diuresis. No inotropic drugs were admin-
istered during the first 20 minutes of reperfusion. After transferring the pa-
tient to the intensive care unit, the rate of infusions was adjusted according
to patient hemodynamic and clinical status by the team on call, who were
unaware of the myocardial protection used.
Myocardial metabolism. Measurements of serum glucose (Bio-
system, Barcelona, Spain), lactic acid (Randox Laboratories Ltd, Crumlin,
United Kingdom), and blood gases (RapidLab 865 blood gas analyzer;
Bayer Diagnostics, Warszawa, Poland) were performed on blood samples
drawn from the aortic root and from the coronary sinus before AXC, imme-
diately after removing the AXC, and 10 and 20 minutes later. Myocardial
oxygen, glucose, and lactic acid extraction ratios were calculated (see
Appendix E1).
Myocardial mitochondria. True-cut needle biopsy specimens ob-
tained by using a 16-gauge needle were taken from the apical left ventricle
before AXC and 1 hour after AXC and placed in cacodyl buffer with 2%
glutaraldehyde. Glutaraldehyde-fixed samples were postfixed with 1% os-
mium, dehydrated with ethanol, fixed with propylene oxide, and then em-
bedded in epoxy resin. After polymerization in increasing temperatures,
semithin sections were obtained with an ultramicrotom (Reichert, Vienna,
Austria) and stained with toluidine blue. Ultrathin sections were placed
on copper grids and stained with uranyl acetate and lead citrate. The mito-
chondria were micrographed with a JEOL-JEM 100CX transmission elec-
tron microscope (JEOL, Inc, Peabody, Mass) at 16,0003 magnification.
The electron micrographs were next saved at 300-dpi resolution, and the
median surface area in pixels of all mitochondria with the outline com-
pletely within the photograph was established on 3 photographs from every
sample. On average, 15.4  6.8 mitochondria were measured per photo-
graph.
Myocardial enzymes. Troponin I (immunoenzymatic method; Bio-
merioux, Lyon, France) and creatine kinase–MB (CK-MB; immunokinetic
method; Thermo Electron Co, Altrincham, United Kingdom) levels were
measured before the operation and 6, 24, and 48 hours after removing the
AXC. N-terminal prohormone brain natriuretic peptide (NT-proBNP)
plasma levels were measured before the operation, 24 hours after removing
the AXC, and 5 days postoperatively (immunoenzymatic method; Biomed-
ica, Bratislava, Slovakia).
Patient Characteristics
Mean patient age was 61  8 and 64  7 years (P¼ .2) in the diazoxide
and placebo groups, respectively. There were 15 and 12 (P¼ .5) female pa-
tients in each group, respectively. Mean Canadian Cardiovascular Society
class was 2.6  0.7 and 2.4  0.8 (P ¼ .6), and ejection fraction was
51%  5% and 50%  5% (P ¼ .5), respectively. No statistically signif-
icant differences were found in clinical characteristics between the groups
(see Table E1).
In all patients the left internal thoracic artery was anastomosed to the left
anterior descending artery, and 2 or 3 saphenous vein grafts were con-
structed. The mean number of distal anastomoses was 3.1  0.2 in the diaz-
oxide group and 3.3  0.7 in the placebo group (P¼ .2). AXC time was 41
 9 and 45  9 minutes (P ¼ .1), and CPB time was 79  9 and 86  18
minutes (P ¼ .2), respectively.
Statistical Methods
Preoperative data are presented as means standard deviation, and post-
operative outcomes are presented as means  standard error of the mean.
Mixed-effects modeling for repeated measures, with protection type as
a fixed factor and time of measurement as random factor, was used to com-
pare the time course of different parameters. Preoperative parameter valuesrgery c April 2009
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MAP (mm Hg) SVRI (dynes $ s1 $ m2 $ cm5) CVP (mm Hg)
Diazoxide group Placebo group Diazoxide group Placebo group Diazoxide group Placebo group
Before AXC 60  4 62  3 1948  123 1981  104 2  1 2  1
After cardioplegia 32  2 34  2 1192  93 1173  67 2  1 2  1
2 Min after 50  5 48  3 1692  173 1556  98 3  1 3  1
Before cardioplegia 62  4 60  3 2028  150 1988  102 2  1 1  1
After cardioplegia 39  4 36  3 1446  130 1368  120 2  1 3  1
2 Min after 51  4 50  3 1694  130 1661  127 1  2 2  1
End of AXC 59  4 63  3 2002  138 2050  118 1  1 1  1
End of CPB 61  3 88  24 1868  109 3050  915 1  3 3  1
All data are presented as means  standard error of the mean. Diazoxide group, n ¼ 20; placebo group, n ¼ 20. Mixed-effects modeling with protection type as fixed and time as
random factor was used (systemic vascular resistance index: protection, P¼ .9; mean arterial pressure: protection, P¼ .4; central venous pressure: protection, P¼ .4). MAP, Mean
arterial pressure; SVRI, systemic vascular resistance index; CVP, central venous pressure; AXC, aortic crossclamp; CPB, cardiopulmonary bypass.C
P
Swere included in the analysis as covariates with random effect. Where a sin-
gle value for the entire evaluation period is given, it is a marginal mean es-
timated from the mixed-effects model. The same model was used to estimate
the mean difference between the groups. Patient characteristics and outcome
data at a given time point were compared by using the t test. Qualitative data
were compared with Fisher’s exact test.
The size of mitochondria in biopsy specimens before and after the oper-
ation was expressed as the mean  standard error and compared with 2-way
analysis of variance. SPSS for Windows 14.0 (SPSS, Inc, Chicago, Ill) was
used for statistical analysis.
RESULTS
Intraoperative Course
The diazoxide group received a total of 1575 52 mL and
the placebo group received a total of 1620  83 mL of car-
dioplegia (P ¼ .6), which corresponded to 36.2  1.2 mg of
diazoxide and 37.3  1.9 mg of placebo (P¼ .6). No differ-
ences in systemic vascular resistance index changes and
mean arterial pressure changes were observed between
groups (Table 1). During CPB, intervention to increase arte-
rial pressure was necessary in 16 patients in the diazoxide
group and 14 patients in the placebo group (P ¼ .7). On av-
erage, 5.5  1.5 and 4.6  1.3 mL of 1:100,000 norepineph-
rine per patient was administered in the diazoxide and
placebo groups, respectively (P ¼ .6). Intervention to lower
arterial pressure was undertaken in 6 patients receiving diaz-
oxide and 2 patients receiving placebo (P ¼ .2).
Two patients in the diazoxide group and 3 in the placebo
group (P ¼ 1.0) required DC shock after declamping the
aorta. All others regained sinus rhythm spontaneously.
Myocardial Metabolism
We observed significant differences in myocardial metab-
olism between the groups in the early phase of reperfusion
(Figure 1). The differences were most pronounced 10 min-
utes after removing the AXC.
At 10 minutes of reperfusion, the myocardial oxygen ex-
traction ratio (O2ER) was significantly higher in comparison
with the preischemic value in the placebo group (53% 
3% vs 47%  3%, P ¼ .02) but did not differ in patientsThe Journal of Thoracic and Ctreated with diazoxide (44%  3% vs 46%  3%, P ¼
.2); there was a significant difference between the groups
(P ¼ .009). After 20 minutes of reperfusion, the myocardial
O2ER was practically back to preischemic values in both
groups. In a mixed-effects model the myocardial O2ER in
reperfusion was significantly higher in the placebo group
(P ¼ .02; Figure 1, A).
Myocardial glucose consumption in reperfusion assessed
with the glucose extraction ratio was lower in the diazoxide
group (P ¼ .03; Figure 1, B). Glucose extraction was very
high immediately after AXC and decreased over 20 minutes
of reperfusion to almost preischemic levels. Characteristi-
cally, at 10 minutes of reperfusion, the glucose extraction ra-
tio was significantly above the preischemic level only in the
placebo group (P¼ .001), and at this time point, a difference
between the 2 groups was observed (P ¼ .03).
Lactic acid production by the myocardium resulted in
a negative lactate extraction ratio. It returned to preischemic
values within 10 minutes of reperfusion in the diazoxide-
treated group but required 20 minutes of reperfusion to nor-
malize in the placebo group (Figure 1, C). Myocardial lactic
acid production was significantly higher 10 minutes after
AXC in the placebo group than in the diazoxide group
(–55%  14% vs –24%  6%, respectively; P ¼ .04).
Mitochondria
The size of mitochondria in the left ventricular myocar-
dium increased during ischemia and reperfusion, from
8474  163 pixels to 11,357  759 pixels (P ¼ .004) in
the placebo group, whereas diazoxide prevented ischemia
and reperfusion–induced mitochondrial swelling (8899 
474 vs 9273  688 pixels before and after the procedure,
respectively; P ¼ .6). The different influence of time on
mitochondrial size in the 2 groups was confirmed by means
of 2-way analysis of variance (P ¼ .03, Figure 2).
Postoperative Course
No death, perioperative myocardial infarction, or stroke
occurred. One re-exploration for bleeding was necessary inardiovascular Surgery c Volume 137, Number 4 999
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in the placebo group. Patients were ventilated for 15.6  0.9
hours in the diazoxide group and 19.5 1.0 hours in the pla-
cebo group (P ¼ .007).
All patients were weaned off CPB with the help of infusion
of 5 mg $ kg1 $ min1 dopamine. No other inotropes or intra-
aortic balloon counterpulsation was necessary. Dopamine
infusion was gradually weaned off within 24 hours in the di-
azoxide group, whereas its maintenance appeared necessary
in the placebo group (P ¼ .005). One day after AXC, diazo-
xide group patients were receiving a mean dopamine dose of
1.6  0.5 mg $ kg1 $ min1, whereas placebo group patients
were receiving 4.1  0.4 mg $ kg1 $ min1 (P<.001). Even
with lower inotropic support in the postoperative period,
mean cardiac index was 0.4  0.1 L $ min1 $ m2 higher
(P ¼ .002) in the diazoxide group than in the placebo group
(Figure 3). Neither central venous pressure (6.6  0.3 vs 6.8
 0.3 mm Hg, P¼ .7), pulmonary capillary wedge pressure
(8.5  0.3 vs 8.0  0.3 mm Hg, P ¼ .3), mean arterial
pressure (75  1 vs 72 1 mm Hg, P¼ .063), nor mean pul-
monary artery pressure (16.9  0.5 vs 17.1  0.5 mm Hg,
P ¼ .8) differed between the groups. Postoperative systolic
blood pressure was significantly higher in the diazoxide
group (113  2 vs 106  2 mm Hg, P ¼ .02), whereas sys-
temic vascular resistance index did not change. Left ventric-
ular work index was higher by 0.51 0.095 kg/m2 (P<.001)
in the diazoxide group postoperatively (Figure 4). Oxygen
delivery index was higher by 48  21 mL $ min1 $ m2
(P¼ .02) in the diazoxide group (see Figure E1), but postop-
erative oxygen consumption remained similar in both groups
(127  3 vs 121  3 mL $ min1 $ m2, P ¼ .2). As a result,
the postoperative O2ER was lower in the diazoxide group
(29.3%  1.1% vs 32.6%  1.1%, P ¼ .004).
Myocardial Enzymes
Neither postoperative troponin I (P¼ .3) nor CK-MB (P¼
.3) levels differed significantly between the groups. The
highest postoperative troponin I level occurred at 6 hours
after AXC and reached a value of 2.5 0.4 ng/mL in the pla-
cebo group and 1.8 0.2 ng/mL in the diazoxide group (P¼
.2). CK-MB levels were highest 24 hours after removing the
AXC (53.0  8.5 and 50.4  8.0 IU/L in the placebo and
diazoxide groups, respectively; P ¼ .8). The NT-proBNP
level increased significantly in the postoperative period
FIGURE 1. Myocardial metabolism during the first 20 minutes after aortic
crossclamp (AXC) removal. All data are presented as means  standard er-
ror of the mean. Mixed-effects modeling with protection type as fixed and
time as random factor was used (n ¼ 20 for every group). *P<.05 between
groups at the same time point. A, Oxygen extraction ratio (O2ER; (protec-
tion, P ¼ .017). B, Glucose extraction ratio (Glucose ER; protection,
P ¼ .033). C, Lactic acid extraction ratio (Lactate ER; protection, P ¼
.077).
urgery c April 2009
Deja et al Cardiopulmonary SupportFIGURE 2. Electrophotomicrographs of left ventricular myocardial mitochondria from the diazoxide group before (A) and after (B) ischemia and reperfu-
sion and the placebo group before (C) and after (D) ischemia and reperfusion. (Original magnification 316,000.) The middle panel shows the influence of
diazoxide on the mitochondria size (pixels) before (Pre op) and after (Post op) ischemia and reperfusion. Data are presented as means  standard error of the
mean. Two-way analysis of variance was used to check the influence of time and protection type on mitochondrial size (protection, P ¼ .1; time, P ¼ .005;
time 3 protection, P ¼ .03). *P< .05 between groups at the same time point.C
P
S(P¼ .001). Its concentration was, on average, 72 35 pg/mL
less in the diazoxide group (P ¼ .04, Figure 5).
DISCUSSION
The current study supports the safety of supplementing
blood cardioplegia with 100 mmol/L diazoxide because we
did not observe the negative effect on blood pressure that
has been reported in a porcine model during reperfusion1
or with adenosine supplementation.18 This was not unex-
pected because an intravenous bolus dose of 1 mg/kg diaz-
oxide causes only around a 10% decrease in blood
pressure.19 Indeed, postoperative systolic blood pressure in
this experiment was actually higher in the diazoxide-treated
patients, possibly related to a higher cardiac index because
all other hemodynamic parameters remained equal. Further-
more, the study corroborates the protective mechanism
afforded by diazoxide against ischemic mitochondrial swell-
ing. Diazoxide increases mitochondrial volume, presumably
by opening mitochondrial KATP channels. These subtle
changes are undetectable microscopically13 but are thought
to bring inner and outer mitochondrial membrane enzymes
closer and hence facilitate phosphorylation. Conversely, is-
chemic swelling is caused by increased mitochondrial
permeability transition pore opening, which leads to micro-
scopically obvious swelling and eventually rupture of the
mitochondrion.5 Diazoxide has been shown to significantly
reduce this phenomenon in isolated rat mitochondria11 and
in an in vivo porcine model.12 The current data confirm these
findings for the first time in clinical settings.The Journal of Thoracic and COur study also confirms the beneficial influence of diazo-
xide on myocardial metabolism during ischemia and reper-
fusion. Increased oxygen consumption in reperfusion, as
observed 10 minutes after removing the AXC in the placebo
group, has long been recognized as a characteristic ‘‘oxygen
debt,’’20 and reduced oxygen consumption during this phase
has served as a marker of better myocardial protection.21 In
FIGURE 3. Cardiac index (CI) before the operation, before cardiopulmo-
nary bypass (CPB), and within the first 24 hours postoperatively. Data are
presented as means  standard error of the mean. Mixed-effects modeling
with protection type as fixed and time as random factor was used (protec-
tion, P ¼ .002). *P< .05 between groups at the same time point (n ¼ 20
for every group).ardiovascular Surgery c Volume 137, Number 4 1001
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protected hearts. The mechanism of action is still debatable
but might be KATP channel independent because pinacidil (a
nonselective KATP channel activator)–based cardioplegia in
a rabbit model resulted in higher oxygen consumption dur-
ing reperfusion than potassium cardioplegia.22 Increased
glucose consumption and lactic acid production can be con-
sidered a sign of still uncoupled glycolysis and glucose ox-
idation with an inability to metabolize pyruvate in the Krebs
cycle.23 It was shown that diazoxide leads to tighter apposi-
tion of specialized sites on internal and external mitochon-
drial membranes associated with coupling to cytosol
creatine kinase2 and as a result allows for fatty acid transport
into the mitochondrion3 and speeds up oxidative phosphor-
ylation.4 The faster recovery of oxidative metabolism with
no lactate production observed in the diazoxide group could
FIGURE 4. Left cardiac work index (LCWI; A) and right cardiac work in-
dex (RCWI; B) before the operation, before cardiopulmonary bypass (CPB),
and within the first 24 hours postoperatively. Data are presented as means 
standard error of the mean. Mixed-effects modeling with protection type as
fixed and time as random factor was used (left cardiac work index: protec-
tion, P< .001; right cardiac work index: protection, P ¼ .1). *P< .05
between groups at the same time point (n ¼ 20 for every group).1002 The Journal of Thoracic and Cardiovascular Spotentially be attributed to this mechanism. Previous reports
of increased mitochondrial respiratory rate13 and higher
adenosine triphosphate levels14 after ischemia in diazo-
xide-treated isolated rat hearts further support our data.
The positive metabolic effect of diazoxide in our study
was most likely caused by direct intracoronary application
during ischemia because preoperative intravenous infusion
to induce ‘‘preconditioning’’ has failed to show a similar ef-
fect.10 Similarly, in our previous experiments on isolated hu-
man myocardium, diazoxide prevented ischemic contracture
only when present during ischemia and not as a precondition-
ing agent.18 These observations were supported by the find-
ings of other investigators in isolated mitochondria.11
The current study failed to find significant differences
in CK-MB and troponin I levels in the postoperative period
between the groups. Most experimental studies show that
diazoxide significantly protects against ischemia-induced
myocardial necrosis.1,8,9,15,17 However, many of these tested
diazoxide-mediated protection against no protection. In
a cardiac surgical rabbit model, potassium/magnesium car-
dioplegia decreased the size of myocardial infarction after
30 minutes of ischemia from 27.8%  2.4% to 3.7% 
0.5%, and administration of diazoxide further reduced the
infarction area to 1.5%  0.4%.16 Therefore the small but
potentially important benefit of diazoxide supplementation
on myocardial necrosis might not be reflected in differential
myocardial enzyme levels. Similarly low necrosis marker
concentration in our relatively ‘‘healthy’’ placebo group un-
dergoing rather uncomplicated and short coronary artery
grafting procedures could mask the influence of diazoxide
on myocardial cell death.
The positive effect of diazoxide on postoperative cardiac
function without reduction of myocardial necrosis suggests
FIGURE 5. N-terminal prohormone brain natriuretic peptide (NT-
proBNP) levels preoperatively (pre-op) and within 5 days postoperatively.
Bars depict means  standard error of the mean. Mixed-effects modeling
with protection type as fixed and time as random factor was used (protec-
tion, P ¼ .048; n ¼ 20 for every group).urgery c April 2009
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less inotropic support, diazoxide-treated patients had a sig-
nificantly higher mean postoperative cardiac index with sim-
ilar loading conditions. Improved myocardial function was
further documented by significantly higher left ventricular
cardiac work index, which is often regarded as the best clin-
ical surrogate of contractility.24 It is tempting to conjecture
that increased contractility resulted in a significantly higher
oxygen delivery index and, as a result, 3%  1% lower
O2ER in the diazoxide group in the postoperative period.
This difference might appear small, but a reduction of mixed
venous oxygen saturation by 5% has been described as a pre-
dictor of postoperative complications.25
Lower postoperative NT-proBNP levels observed in the
diazoxide group might reflect less myocyte stretch resulting
from better diastolic or systolic function. Although the pre-
dictive value of postoperative NT-proBNP measurement has
not been unanimously established, it is likely that postoper-
ative NT-proBNP levels correlate with the probability of
cardiovascular events26 and myocardial remodeling after
acute myocardial infarction.27 Studies with sevoflurane as
a preconditioning agent suggest that lower postoperative
NT-proBNP levels reflect better myocardial protection.28
In conclusion, the current study has confirmed the safety
of diazoxide supplementation to blood cardioplegia in a se-
lected group of low-risk cardiac surgical patients. We have
also demonstrated a positive effect on myocardial metabo-
lism and postoperative function. Further clinical studies
are needed to better define the role of diazoxide-based cardi-
oplegia in the surgical armamentarium.
This work represents primarily a safety study, and there-
fore only a small number of relatively healthy patients with
well-preserved left ventricular function undergoing an un-
complicated cardiac procedure were included. Because of
this, no attempt has been made to extrapolate clinical
endpoints from these data. At the same time, the choice of
the study group decreased the chance of finding a positive
treatment effect. Not surprisingly, the differences observed
(functional and metabolic) were small and transient. We ac-
knowledge that ideally the amount of necrosis and apoptosis
should have been assessed directly in biopsy specimens.
Having a limited amount of tissue, we decided to concentrate
on mitochondrial assessment, but this limitation must be duly
acknowledged.
We excluded diabetic patients from the study because sul-
fonylurea derivatives often used in type 2 diabetes mellitus
inhibit KATP channels and might therefore affect diazoxide’s
action.29 Many authors also believe that preconditioning
mechanisms are impaired in diabetes,17 and additionally,
diazoxide has intrinsic hyperglycemic properties.
Our study group had a high percentage of female patients.
It has been recently suggested, based on an animal study,
that diazoxide might be less effective in preventing postis-
chemic function loss, myocardial infarction, and mitochon-The Journal of Thoracic and Cdrial calcium overload and dysfunction in female subjects,
particularly with increasing age.30 Our group is obviously
too small to comment on sex differences. However, the dis-
tribution of female subjects was equal between the groups,
and it is possible that the observed functional and metabolic
differences might be magnified in a male population.
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SAPPENDIX E1. FORMULAE USED FOR
CALCULATION OF HEMODYNAMIC AND
METABOLIC PARAMETERS
Myocardial metabolism in reperfusion
Parameters measured:
 Hemoglobin concentration (Hgb)
 Arterial partial pressure of oxygen (PaO2)
 Arterial hemoglobin oxygen saturation (SatO2)
 Arterial concentration of glucose ([glucose]a)
 Arterial concentration of lactate ([lactate]a)
 Coronary sinus partial pressure of oxygen (PvO2)
 Coronary sinus hemoglobin oxygen saturation (SatvO2)
 Coronary sinus concentration of glucose ([glucose]v)
 Coronary sinus concentration of lactate ([lactate]v)
Parameters calculated:
 Arterial oxygen content
CaO2 ¼ ð1:38  Hgb  SatO2Þ  ð0:0031  PaO2Þ
 Coronary sinus oxygen content
CvO2 ¼ ð1:38  Hgb  SatvO2Þþð0:0031  PvO2Þ
 Myocardial oxygen extraction ratio
O2ER ¼ CaO2--CvO2
CaO2
 Myocardial glucose extraction ratio
GlucoseER ¼ ½glucosea--½glucosev½glucosea
 100
 Myocardial lactate extraction ratio
LactateER ¼ ½lactatea--½lactatev½lactatea
 100
Hemodynamic parameters during cardiopulmonary
bypass
Parameters measured:
 Pump output
 Mean arterial pressure (MAP)
 Central venous pressure (CVP)
Parameters calculated:
 Systemic vascular resistance index
SVRI ¼ ðMAP--CVPÞ  BSA
pump output
 80The Journal of Thoracic and CarHemodynamic parameters in first postoperative 24
hours
Parameters measured:
 Cardiac output with thermodilution method
CO ¼ VðTB--TIÞðSI  CIÞ  60CT  K
A  ðSB  CBÞ!
where V ¼ injected volume, A ¼ area under the temperature
curve, K ¼ calibration constant, TB ¼ blood temperature,
Ti ¼ temperature of injectate, SB ¼ blood-specific weight,
SI ¼ injectate-specific weight, CB ¼ blood-specific heat ca-
pacity, SI ¼ injectate-specific heat capacity, CT ¼ correction
for injectate heating
 Heart rate (HR)
 Mean arterial pressure (MAP)
 Mean pulmonary artery pressure (MPAP)
 Central venous pressure (CVP)
 Pulmonary capillary wedge pressure (PCWP)
 Hemoglobin concentration (Hgb)
 Arterial partial pressure of oxygen (PaO2)
 Arterial hemoglobin oxygen saturation (SatO2)
 Mixed venous partial pressure of oxygen (PMVO2)
 Mixed venous hemoglobin oxygen saturation (SatMVO2)
Parameters calculated:
 Cardiac index
CI ¼ CO
BSA
 Systemic vascular resistance index
SVRI ¼ MAP--CVP
CI
 80
 Pulmonary vascular resistance index
PVRI ¼ MPAP--PCWP
CI
 80
 Left cardiac work index
LCWI ¼ CI MAP  0:0144
 Right cardiac work index
RCWI ¼ CI MPAP  0:0144
 Arterial oxygen content
CaO2 ¼ ð1:38  Hgb  Sat O2Þþð0:0031  Pao2Þdiovascular Surgery c Volume 137, Number 4 1004.e1
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S Oxygen delivery index
DO2I ¼ CI  CaO2  10
 Mixed venous oxygen content
CMVO2 ¼ ð1:38  Hgb  SatMVO2Þþð0:0031  PMVO2Þ
FIGUREE1. Oxygen delivery index (DO2I) before the operation (pre-op),
before cardiopulmonary bypass (CPB), and within the first 24 hours postop-
eratively. Data are presented as means standard error of the mean. Mixed-
effects modeling with protection type as fixed and time as random factor was
used (protection, P ¼ .02). *P<.05 between groups at the same time point
(n ¼ 20 for every group).1004.e2 The Journal of Thoracic and Cardiovascular S Oxygen consumption index
VO2I ¼ CI  Cða--vÞO2  10
 Oxygen extraction ratio
O2ER ¼ CaO2--CMVO2
CaO2
 100
TABLE E1. Patient characteristics
Diazoxide
group
(n ¼ 20)
Placebo
group
(n ¼ 20) P value
Age (y) 61  8 64  7 .2
Sex
Male 5 (25%) 8 (40%) .5
Female 15 (75%) 12 (60%) .5
CCS class 2.6  0.7 2.4  0.8 .6
Ejection fraction (%) 51  5 50  5 .5
Previous myocardial infarction 10 (50%) 11 (55%) 1.0
Coronary artery
disease risk factors
Hypertension 12 (60%) 14 (70%) .7
Hyperlipidemia 12 (60%) 13 (65%) 1.0
Smokers
Current 3 (15%) 4 (20%) 1.0
Past 12 (60%) 7 (35%) .2
Diabetes mellitus 0 0
Treatment
ACEI 14 (70%) 17 (85%) .5
b-Blockers 17 (85%) 18 (90%) 1.0
Ca2þ blockers 3 (15%) 2 (10%) 1.0
Statins 11 (55%) 16 (80%) .2
Aspirin 1 (5%) 0 1.0
CCS, Canadian Cardiovascular Society; ACEI, angiotensin-converting enzyme
inhibitors.urgery c April 2009
